Methods and devices for treating pulmonary vasoconstriction and

Details Methods and devices for treating pulmonary vasoconstriction and Methods and devices for treating pulmonary vasoconstriction and

1994-04-01

1996-11-05

Lewis, Aaron J.

Surgery

Liquid medicament atomizer or sprayer

12820023, 12820312, A61M 1100

Patent

active

055706835

ABSTRACT:
A method for treating or preventing bronchoconstriction or reversible pulmonary vasoconstriction in a mammal, which method includes (a) causing the mammal to inhale a therapeutically-effective amount of gaseous nitric oxide and (b) introducing into the mammal a therapeutically-effective amount of a phosphodiesterase inhibiting compound; and an inhaler device containing nitric oxide gas and a phosphodiesterase inhibiting compound.

REFERENCES:
patent: 3785377 (1974-01-01), Jorgensen
patent: 4010897 (1977-03-01), Treharne et al.
patent: 4287040 (1981-09-01), Alamaro
patent: 4297123 (1981-10-01), Wyse et al.
patent: 4336798 (1982-06-01), Beran
patent: 4534343 (1985-08-01), Nowacki et al.
patent: 4592348 (1986-06-01), Waters, IV et al.
patent: 4667668 (1987-05-01), Wetterlin
patent: 4852561 (1989-08-01), Sperry
patent: 4877589 (1989-10-01), O'Hare
patent: 4915915 (1990-04-01), Treharne
patent: 4954526 (1990-09-01), Keefer
patent: 5155137 (1992-10-01), Keefer et al.
patent: 5178138 (1993-01-01), Walstrom et al.
patent: 5208233 (1993-05-01), Keefer et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5260210 (1993-11-01), Rubin et al.
patent: 5396882 (1995-03-01), Zapol
patent: 5427797 (1995-06-01), Frostell et al.
"Influence of Zaprinast on Vascular Tone and Vasodilator Responses In the Cat Pulmonary Vascular Bed", by McMachon et al., J. Appl. Physiology 74(4), 1993, pp. 1704-1711.
Blomqvist et al., Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator Reversing Human Hypoxic Pulmonary Vasoconstriction (HPV), Circulation 84:361, 1991.
Desai et al., Involvement of Nitric Oxide in the Reflex Relaxation of the Stomach to Accommodate food or Fluid, Nature 351:477, 1991.
Donahoe et al., Production of O.sub.3, NO, and N.sub.2 O in a Pulsed Discharge at 1 Atm, Ind. Eng. Chem. 16:208-215, 1977.
Fractacci et al., Inhaled Nitric Oxide, Anesthesiology 75:990-999, 1991.
Pepke-Zaba et al., Inhaled Nitric Oxide as a Cause of Selective Pulmonary Vasodilation in Pulmonary Hypertension, The Lancet 338:1173-1174, 1991.
Rimar et al., Prolonged Duration of Inhaled Nitric Oxide Induced Vasodilation in Perfused Rabbit Lungs Circulation 84:362, 1991.
Roberts, Jr. et al., Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator for the Treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), Circulation 84:1279, 1991.
Dupuy et al., Bronchodilator Action of Inhaled Nitric Oxide in Guinea Pigs, J. clin. Invest. 90:421-428, 1992.
Kacmarek et al., Nitric Oxide as a Bronchodilator in Methacholine Induced Bronchospasm in Mild Asthmatics, 1993 ALA/ATS International Conference, May 16-19, 1993, San Francisco, CA #21556 (Abstract).
Messent et al., The Pulmonary Physician and Critical Care, Thorax 47:651-656, 1992.
Swami et al., the Pulmonary Physician and Critical Care, Thorax 47:555-562, 1992.
Frostell, MD,PhD et al., Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction, Circulation 83:2038-2047, 1991.
Dalby et al., Comparison of Output Particle Size Distributions from Pressurized Aerosols Formulated as Solutions or Suspensions, Pharmac. Re. 5:36-39, 1988.
Buga et al., Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle, European J. of Pharmc. 161:61-72, 1989.
Ishii et al., A Simple and Sensitive Bioassay Method for Detection of EDRF with RFL-6 Lung Fibroblasts, Am. J. Physiol. 261:H598-H603, 1991.
Contractor et al., Development and Evaluation of an Inhalation Aerosol of Nitroglycerin, J. Pharm. Sci. 63:907-911, 1974.
Jansen et al., The Relaxant Properties in Guinea Pig Airways of S-Nitrosothiols, J. Pharmacology and Experimental Therapeutics 261:154-160, 1992.
Kreye et al., Comparison of Sodium Nitroprusside and Isoprenaline Aerosols in Histamine-Induced Bronchial Asthma of the Guinea Pig, Naunyn-Schmiedeberg S Arch Pharmacol. 306:203-207, 1979.
Cremona et al., Endothelium-Derived Relaxing Factor and the Pulmonary Circulation, Lung 169:185-202, 1991.
Dinh Xuan et al., Acetylcholine and Adenosine Diphosphate Cause Endothelium-dependent Relaxation of Isolated Human Pulmonary Arteries, Eur. Respir. J. 3:633-638, 1990.
Dinh Xuan et al., Primary Pulmonary Hypertension: Diagnosis, Medical and Surgical Treatment, Respiratory Medicine 84:189=197, 1990.
Dinh Xuan et al., Non-prostanoid Endothelium-derived Vasoactive Factors, J. International Medical Research 17:305-315, 1989.
Foubert et al., Safety Guidelines for Use of Nitric Oxide, The Lancet 339:1615-1616, 1992.
Naeije et al., Effects of vasodilators on Hypoxic Pulmonary Vasoconstriction in Normal Man, Chest 82: 404-410, 1982.
Flavahan et al., Respiratory Epithelium Inhibits Bronchial Smooth Muscle Tone, J. Appl. Physiol. 58:834-838, 1985.
Hugod, Effect of Exposure to 43 ppm Nitric Oxide and 3.6 ppm Nitrogen Dioxide on Rabbit Lung, Int. Arch. Occup. Environ, Health 42:159-167, 1979.
Nakajima et al., Biological Effects of Nitrogen Dioxide and Nitric Oxide, Nitrogen Oxides 121-141.
Packer, Is It Ethical to Administer Vasodilator Drugs to Patients with Primary Pulmonary Hypertension, Chest 95:1173-1175, 1989.
Norman et al., Nature pp. 915-916, 1965.
Staverrt et al., Nitric Oxide and Nitrogen Dioxide . . . Concentrates for Brief Periods, Inhalation Toxicology 2:53-67, 1990.
Morel et al., Acute Pulmonary Vasoconstriction and Thromboxane Release During Protamine Reversal of Heparin Anticoagulation in Awake Sheep, Circulation Research 62:905-915, 1988.
Morel et al., C5.alpha. and Thromboxane Generation Associated with Pulmonary Vaso-and Broncho Constriction during Protamine Reversal of Heparin, Anesthesiology 66:597-604, 1987.
Borland et al., A Simultaneous single Breath Measurement of Pulmonary Diffusing Capacity with Nitric Oxide and Carbon Monoxide, Eur. Respir. J. 2:56-63, 1989.
Altabef et al., Intravenous Nitroglycerin for Uterine Relaxation of an Inverted Uterus, Am. J. Obstet. Gynecol. 166:1237-1238, 1992.
Oxytocin. Prostaglandins. Ergot Alkaloids. Tocolytic Agents., Chapter 39, pp. 942-945.
Resnick et al., Evaluation and Medical Management of Urinary Incontinence, Anesthesia pp. 3-6, 1992.
Zapol et al., Regional Blood Flow During Simulated Diving in the Conscious Weddell Seal, J. Appl. Physiol. 47:968-973, 1979.
Ignarro et al., Endothelium-Derived Relaxing Factor Produced and Released from Artery Vein is Nitric Oxide, Proc. Natl. Acad. Sci. USA 84:9265-9269, 1987.
Palmer et al., Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor Nature 327:524-526, 1987.
Ignarro, Biological Actions and Properties of Endothelium-Derived Nitric Oxide Formed and Released From Artery and Vein, Dept. Pharmlgy. pp. 23-278.
Higgenbottam et al., Am. Rev. Resp. Dis. Suppl. 137:107, 1988.
Zapol et al., Pulmonary Hypertension in Severe Acute Respiratory Failure, N.E. J. Med. 296:476-480, 1977.
Meyer et al., Nitric Oxide (NO), a New Test Gas for Study of Alveolar-Capillary Diffusion, Eur. Respir. J. 2:494-496, 1989.
Hounam et al., particle Deposition pp. 125-156.
Ignarro, Endothelium-Derived Nitric Oxide: Actions and Properties, FASEB J. 3:31-36, 1989.
Archer et al., Comparison of the Hemodynamic Effects of Nitric Oxide and Endothelium-Dependent Vasodilators in Intact Lungs, J. Appl. Physiol. 68:735-747, 1990.
Furchgott et al., Endothelium-Derived Relaxing and Contracting Factors, FASEB J. 3:2007-2018, 1989.
Archer et al., Hypoxic Pulmonary Vasoconstriction is Enhanced by Inhibition of the Synthesis of an Endothelium Derived Relaxing Factor, Biochem. Biophysl. Re. Comm. 164:1198-1205, 1989.
Brashers et al., Augmentation of Hypoxic Pulmonary Vasoconstriction in the Isolated Perfused Rat Lung by in Vitro Antagonists of Endothelium-Dependent Relaxation, J. Clin. Invest. 82:1495-1502, 1988.
Ignarro et al., Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: . . . S-Nitrosothiols as Active Intermediates, J. Pharmol. Experm. Ther. 218:739-749, 1981.
Kadowitz et al., Pulmonary Vasodilator Responses to Nitroprusside and Nitroglycerin in the Dog, Clin. Invest. 67:893-902, 1981.
Allen and Hanbury, Product In

Affiliated with

Also associated with

Rating

Methods and devices for treating pulmonary vasoconstriction and does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and devices for treating pulmonary vasoconstriction and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and devices for treating pulmonary vasoconstriction and will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2007951